Treace Medical Concepts, Inc. (TMCI) Stock Price & Analysis
Treace Medical Concepts, Inc. (TMCI) rose 5.67% to USD 3.73 as of June 10, 2026 at 00:50 UTC, according to Nexqual real-time market data.
TMCI last closed at USD 3.53; the session ranged USD 3.39–3.75 on volume of 363,920 shares. Market capitalization is $241.98M, with a 52-week range of USD 1.17–7.78 (NMS). Source: Nexqual, June 10, 2026 at 00:50 UTC.
Key Statistics (as of June 10, 2026 at 00:50 UTC)
| Price | USD 3.73 |
|---|---|
| Change | ▲ 5.67% (up) |
| Previous Close | USD 3.53 |
| Open | USD 3.56 |
| Day Range | USD 3.39 – 3.75 |
| 52-Week Range | USD 1.17 – 7.78 |
| Volume | 363,920 shares |
| Market Cap | $241.98M |
| Exchange | NMS |
Technical Analysis (TMCI)
Nexqual's technical model rates TMCI "BUY" based on 5 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 00:50 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 74.39 (overbought) |
| vs SMA50 | Above (USD 2.29) |
| MACD | 0.41 (positive) |
Analyst Ratings (TMCI)
Wall Street analysts rate TMCI "None" based on 3 analysts, with a mean price target of USD 4 (range USD 2–7), per Nexqual as of June 10, 2026 at 00:50 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 4 |
| High Target | USD 7 |
| Low Target | USD 2 |
| Buy / Hold / Sell | 1 / 3 / 1 |
Earnings (TMCI)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.3 |
| Revenue Estimate | $43.92M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.12 vs est -0.31 ▲ beat |
| 2025-12-31 | USD -0.08 vs est -0.14 ▲ beat |
| 2025-09-30 | USD -0.22 vs est -0.27 ▲ beat |
| 2025-06-30 | USD -0.26 vs est -0.29 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:50 UTC.
Financials & Fundamentals (TMCI)
| Total Revenue | $207.32M |
|---|---|
| Revenue Growth (YoY) | -10.20% |
| Gross Margin | +79.72% |
| Operating Margin | -36.37% |
| Profit Margin | -29.44% |
| ROE | -66.88% |
| Debt / Equity | 92.76 |
| Current Ratio | 3.58 |
| Total Cash | $51.85M |
| Total Debt | $71.60M |
| Free Cash Flow | $-5.77M |
Source: Nexqual, June 10, 2026 at 00:50 UTC.
Financial Health Score (TMCI)
Nexqual rates Treace Medical Concepts, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:50 UTC.
| Growth | Mixed — Revenue +1.6% YoY (annual), slow |
|---|---|
| Profitability | Solid — Gross margin 80%, operating -36% |
| Balance Sheet | Mixed — $52M cash vs $72M debt |
| Cash Flow | Weak — FCF negative: -$6M, burning cash |
| Efficiency | Critical — ROE -67%, ROA -17.9% |
Ownership (TMCI)
| Insider Ownership | +25.31% |
|---|---|
| Institutional Ownership | +57.09% |
| Shares Outstanding | 64.87M |
| Float | 47.29M |
| Short % of Float | +6.99% |
Source: Nexqual, June 10, 2026 at 00:50 UTC.
Leadership (TMCI)
Treace Medical Concepts, Inc. is led by John T. Treace (age 53), Founder, Chairman & CEO, per Nexqual as of June 10, 2026 at 00:50 UTC.
| Founder, Chairman & CEO | John T. Treace (age 53) |
|---|---|
| Chief Financial Officer | Mark L. Hair (age 55) |
| Senior Vice President of Sales | Brad Barr |
| Senior Vice President of Clinical Affairs & Reimbursement | Shana Zink |
Major Backers & Investors (TMCI)
Notable institutional backers of Treace Medical Concepts, Inc. include Armistice Capital, LLC, Gagnon Securities, LLC, Bank of America Corporation, according to Nexqual as of June 10, 2026 at 00:50 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Armistice Capital, LLC | 9.81% |
| Gagnon Securities, LLC | 8.02% |
| Bank of America Corporation | 4.95% |
| First Eagle Funds-First Eagle Small Cap Opportunity Fund | 2.05% |
| CIBC Bancorp USA Inc. | 1.88% |
| Millennium Management | 1.77% |
| AQR Capital Management, LLC | 1.64% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 7.52% |
| Vanguard Group | 5.09% |
| State Street | 1.9% |
Source: Nexqual, June 10, 2026 at 00:50 UTC.
From Treace Medical Concepts, Inc.'s Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States.
- It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant.
- In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction.
- Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SGHT | Sight Sciences, Inc. | USD 4.85 | ▲ 8.99% |
| DSGN | Design Therapeutics, Inc. | USD 10.55 | ▼ 0.94% |
| CTKB | Cytek Biosciences, Inc. | USD 4.13 | ▲ 0.98% |
| LUNG | Pulmonx Corporation | USD 1.53 | ▲ 0% |
| CVRX | CVRx, Inc. | USD 5.2 | ▼ 3.35% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:50 UTC. This page is informational and not investment advice.